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Dendritic Cells-Nature and
Classification
Katsuaki Sato1 and Shigeharu Fujita1
ABSTRACT
Dendritic cells (DCs) are antigen (Ag)-presenting cells (APCs) characterized by a unique capacity to stimulate
naïve T cells and initiate primary immune responses. Recent studies suggest that DCs also play critical roles in
the induction of central and peripheral immunological tolerance, regulate the types of T cell immune responses,
and function as sentinels in innate immunity against microbes. The diverse functions of DCs in immune regula-
tion depend on the heterogeneity of DC subsets and their functional plasticity. Here we review recent progress
in our understanding of the nature and classification of DCs.
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INTRODUCTION
The discovery of skin dendritic cells (DC) by Langer-
hans in 1868 was followed by much speculation as to
their function. Steinman and Cohn identified spleen
cells having distinct morphological features with den-
drites prepared from mouse peripheral lymphoid or-
gans in 1973, and termed these potent stimulators of
primary immune responses DCs.1 The observation
that similar leukocytes were present in the nonlym-
phoid tissues of both rodents and humans,2 com-
bined with early evidence suggesting that they played
an important role in heart and kidney transplant re-
jection as well as immune responses,2 generated fur-
ther interest in DCs. However, a low frequency in the
body (1―2% of the total leukocytes)1 and lack of mark-
ers for DCs caused problems with the purification of
DCs as well as slow progress in their further charac-
terization. For the past decade, advances in the in vi-
tro culture of DCs using a cocktail of cytokines and
methods to purify DCs with the availability of mono-
clonal antibodies (mAbs) have provided a reliable
source of these cells for functional and development
studies. It has become clear that DCs follow various
hematopoietic pathways of differentiation and matura-
tion, and the multiple and heterogeneous subsets of
DCs vary in cell surface marker expression.3-6 The
extensive studies to date have revealed that DCs are
critical APCs for not only the induction of primary im-
mune responses, but also for the regulation of the
type of T cell-mediated immune response, including
T type 1 helper (Th1) cell- and Th2 cell-responses.3,4,7
In addition to their role in adaptive responses, DCs
serve as sentinels, recognizing the presence of invad-
ing pathogens through various pattern-recognition re-
ceptors (PRRs), and become activated by microbial
products to secrete proinflammatory cytokines in-
volved in host defense, thereby linking innate and
adaptive immunity.8,9 Conversely, DCs could be also
important for the induction of immunological toler-
ance, and the mechanisms involved include clonal de-
letion of self-reactive T cells in thymus (central toler-
ance) and clonal deletion and anergy as well as active
suppression by the production of T regulatory (TR)
cells in the periphery, a function of likely importance
in autoimmunity and transplant rejection as well as
self-tolerance (peripheral tolerance).10-13 The diverse
functions of DCs in immune regulation reflect the
heterogeneous subsets with different lineages and
maturity, and functional plasticity. In this review, we
attempt to highlight the nature and classification of
DC subsets in humans and mice.
NATURE OF DCS
Hematopoietic progenitors in the bone marrow (BM)
give rise to circulating DC precursors that home to
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Fig. 1 DCs act as natural adjuvants to generate Ag-specific T cels from naïve T cels. Immature DCs sense the 
presence of invading pathogens via various PRRs and process the pathogens intracelularly in inflammatory tis-
sues, and they develop into mature DCs with change of the various functions. Subsequently, mature DCs home 
into secondary lymphoid tissues where they present the processed Ags to naïve T cels to generate efector T 
cels.
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blood as well as non-lymphoid and lymphoid tissues,
where they reside as immature cells. Immature DCs
possess high endocytic and phagocytic capacity per-
mitting Ag capture, but express low levels of MHC
class II (MHC II) molecules and costimulatory mole-
cules on their surface (Fig. 1). Following a microbial
infection and tissue damage, immature DCs migrate
to the inflammatory regions in response to the pro-
duction of a large spectrum of inflammatory chemoki-
nes upon local inflammation through specific recep-
tors (Fig. 1). Immature DCs recognize pathogen-
associated molecular patterns (PAMPs) of microbial
products via PRRs, including the families of Toll-like
receptor (TLR) and mannose-like receptors, and in-
flammatory compounds released by damaged tissues
(Fig. 1). Upon recognizing a pathogen, they release
large amounts of proinflammatory or antiviral cytoki-
nes resulting in the activation of innate immune cells,
thereby limiting the spread of infection (Fig. 1). Si-
multaneously, DCs acquire a “mature” phenotype,
and the maturation process is associated with several
coordinated events such as (a) loss of endocytic and
phagocytic receptors, (b) high-level expression of
MHC II at the cell surface and increased production
of costimulatory molecules, including CD40, CD80,
and CD86, (c) changes in morphology, and (d) activa-
tion of the Ag-processing machinery, including a shift
in lysosomal compartments and increase in DC-
lysosome-associated membrane protein (DC-LAMP)
(Fig. 1). In addition, mature DCs reprogram
chemokine receptor expression and responsiveness,
including the loss of the responsiveness to inflamma-
tory chemokines (e.g., CCL3, CCL5, and CCL20)
through either receptor downregulation or receptor
desensitization (e.g., CCR1, CCR5, and CCR6) and
acquisition of the responsiveness to homeostatic
chemokines, including CCL19 and CCL21 via upregu-
lation of CCR7 (Fig. 1). Consequently, mature DCs
move via the afferent lymphatics into the T-cell area
of local draining lymph nodes (LNs), where they se-
lect rare Ag-specific T cells and induce their activa-
tion and differentiation into effector cells, thereby in-
Classification of Dendritic Cells
Allergology International Vol 56, No3, 2007 www.jsaweb.jp 185
itiating primary immune responses (Fig. 1).
CLASSIFICATION OF DCS BY ANATOMICAL
LOCALIZATION
The level of heterogeneity is reflected by anatomical
localization. DCs and DC precursor cells circulate in
low numbers (approximately 1% of peripheral blood
mononuclear cells [PBMCs]). In non-lymphoid tis-
sues, skin epidermal Langerhans cells (LCs) and der-
mal DCs exist in the skin, and interstitial DCs
(intDCs) are found in most organs, including liver,
kidney, heart, and other connective tissues and tend
to be associated with vascular structures. Mucosal
surface-associated DCs are found in the mucosa of
the oral cavity, intestinal tract, and respiratory tract.
These cells develop from precursors in the blood and
provide a sentinel system in the peripheral tissues. In
lymphoid tissues, the germinal center (GC), which is
the microenvironment that allows the generation of B
cell memory, also contains follicular DCs (FDCs) and
GC DCs (GCDCs). FDCs have the unique capacity to
trap Ag in the form of immune complexes for long pe-
riods of time and promote the activation and selection
of GC B cells. In contrast, GCDCs are strong APCs
for T cells. DCs which have captured Ag, and mi-
grated from the skin, other nonlymphoid interstitial
sites, and the mucosal surfaces into afferent lymph
are recognized as afferent lymphatic DCs (veiled
cells). These cells migrate through the afferant lym-
phatics and become interdigitating DCs (IDCs) in T-
cell areas in the paracortex, which can initiate im-
mune responses by activating naïve T cells, and
probably B cells. In the thymus, thymic DCs are sug-
gested to be involved in the negative selection of T
cells. Although certain phenotypic differences have
been observed among these different DC subsets, the
cell’s origins, maturation stages, and functional differ-
ences have not been clearly established. A DC
lineage-specific marker has not yet been identified,
and the subsets of DCs in humans and mice are
therefore currently defined by linage−MHC II+cells in
combination with various cell surface markers.
HETEROGENEITY OF MOUSE DC SUBSETS
SUBSETS OF CONVENTIONAL MOUSE DCS
Multiple DC subsets have now been defined in
mouse lymphoid organs on the basis of cell surface
marker expression. Mouse DCs are basically defined
by their expression of CD11c and MHC II in combi-
nation with CD4, CD8α, CD11b, and CD205. The T-
cell markers CD4 and CD8 are expressed on mouse
DCs and are useful for segregating subsets. CD8 on
DCs is in the form of an αα-homodimer rather than
the αβ-heterodimer that is typical of T cells. In the
past, CD8α+DCs have been referred to as “lymphoid
DCs” and CD8α−DCs as “myeloid DCs”, although
this concept is now thought to be inappropriate.14
Other markers that are useful for segregating mouse
DC subsets include the myeloid cell marker CD11b
and the interdigitating DC marker CD205. Using
these cell surface markers, five conventional subsets
of CD11c+MHC II+DCs can be found in lymphoid tis-
sue under steady-state conditions. The spleen con-
tains three subsets, including CD4−CD8αhighCD205+
CD11b−lymphoid DCs (20% of spleen DCs), CD4+
CD8α−CD205−CD11b+myeloid DCs (40% of spleen
DCs), and CD4−CD8α−CD205−CD11b+myeloid DCs
(15% of spleen DCs)15 (Table 1). Both CD4+CD8α−
CD205−CD11b+myeloid DCs and CD4−CD8α−CD205−
CD11b+ myeloid DCs of spleen and LNs that also ex-
press 33D1 and F480, are located in the marginal
zone between white and red pulp,15 and migrate to
the T-cell area upon stimulation.16 Both CD8α−sub-
sets are efficient stimulators of CD4+ and CD8+T cells
in vitro, and can direct a Th2-type immune response
in vivo (Fig. 2).17 CD4−CD8αhighCD205+CD11b− lym-
phoid DCs occupy the T-cell area of spleen, and are
also found at moderate levels in LNs, but are the
dominant subset among thymic DCs.15,18,19 Freshly
isolated CD4−CD8αhighCD205+CD11b−lymphoid DCs
have a regulatory effect on T cells in which they acti-
vate both CD4+ and CD8+T cells, but can induce apop-
tosis in CD4+T cells and a limited CD8+T cell re-
sponse.20 Moreover, they are responsible for main-
taining peripheral tolerance under steady-state condi-
tions through the induction of cross-tolerance.21,22 In
this role, they may function to maintain T-cell toler-
ance in lymphoid organs in the absence of infection.
In contrast, under conditions consistent with activa-
tion, CD4−CD8αhighCD205+CD11b−lymphoid DCs
can not only activate CD8+T cells but also cross-
present for the stimulation of cytotoxic T cells (Fig.
2).23,24 In addition, they can trigger the development
of Th1 cells in vivo (Fig. 2), consistent with activated
CD4−CD8αhighCD205+CD11b−lymphoid DCs being
the major producers of interleukin (IL)-12.17,25-27 In
addition to the three subsets described in spleen,
LNs contain two extra DC subsets that are not nor-
mally found in spleen, which apparently arrived via
the lymphatic system.18,28,29 They represent the ma-
ture form of interstitial tissue DCs which are CD4−
CD8α−CD205+CD11b+myeloid subsets, and LCs
which are CD4−CD8αlowCD205highCD11b+myeloid
subsets (Table 1). Mature LCs are restricted mainly
to the skin-draining LNs, while mature interstitial tis-
sue DCs are common to all LNs. LCs in LNs are dis-
tinguished by their expression of langerin and very
high levels of MHC II and costimulatory molecules.
They appear to be fully activated DCs and efficient
stimulators of naïve CD4+T cells to possibly generate
Th1 cells (Fig. 2).29 However, the migration of DC
subsets from peripheral tissue into LNs occurred in
the absence of infection,30 suggesting that the steady-
state migration of semi-mature DCs from tissue to
LNs occurs naturally during the maintenance of pe-
ripheral tolerance.31
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Table 1 Heterogeneity of murine DCs
＊PlasmacytoidConventional
DC Subsets
IPCs
Lymph nodesSpleen and Lymph nodes
CD4－CD8α－CD4－CD8αlowCD4＋CD8α－CD4－CD8α－CD4－CD8αhigh
Lymphoid/MyeoildMyeloidMyeloidMyeloidMyeloidLymphoidLineage
Phenotype
var.－var.－－＋＋＋CD8α
var.－－＋＋－－CD4
－＋＋＋＋＋＋var.－CD11b
＋＋＋＋＋＋＋＋＋＋＋var.＋＋＋CD11c
＋＋＋＋＋－－＋＋＋CD205
－－－＋＋－－33D1
＋＋－－－－－B220
＋＋－－－－－Gr-1
＋＋＋－－－－－128G
＋＋＋－－－－－440c
＋＋＋－－－－－mPDCA-1
－＋＋＋＋＋＋＋,－＋CD40
－＋＋＋＋＋＋＋,－＋CD80
－＋＋＋＋＋＋＋,－＋CD86
＋＋＋＋＋＋＋＋＋＋＋＋＋＋＋＋＋MHCI
－－＋＋＋－－－Langerin
Al areaAlSkin-drainingAnatomical site
lymph nodeslymph nodesMarginal zoneMarginal zoneT-cel area
－, negative; ＋, low; ＋＋, intermediate; ＋＋＋, high; var., heterogenous.
＊Plasmacytoid DCs can be CD4－CD8α＋, CD4＋CD8α－, CD4－CD8α－, CD4＋CD8α＋subsets, and they are found mostly in the peri-
arteriolar lymphoid sheaths, but scatered plasmacytoid DCs are present in the marginal zone and red pulp.
MOUSE PLASMACYTOID DCS
Plasmacytoid DCs, which were originally identified in
humans, represent a distinct class of DCs newly iden-
tified in spleen (25% of spleen DCs) as well as BM,
thymus and lymph nodes in mice.32-34 Plasmacytoid
DCs display characteristics different from other “con-
ventional” DC subsets, but share most of the morpho-
logical and functional characteristics of their human
counterparts. While conventional DC subsets enter
LNs from peripheral tissues, plasmacytoid DCs enter
directly from blood by crossing the high endothelial
venule (HEV) though CD62L.32 Freshly isolated plas-
macytoid DCs have a morphology typical of that of
large, round cells with a diffuse nucleus and few den-
drites, and express B220 and Gr-1 together with CD8
α, CD11c, CD205 and MHC II and lack costimulatory
molecules (Table 1). Recently, mouse plasmacytoid
DC-restricted surface markers have been identified
with three additional Abs, 120G8 Ab, 440c Ab, and
mPDCA-1 Ab (Table 1). They exhibit poor capacity to
stimulate T cells, and may play a role in the mainte-
nance of peripheral tolerance under steady-state con-
ditions.35 Activation of plasmacytoid DCs improves
their viability in culture and upregulates their expres-
sion of CD8α, MHC class II, and costimulatory mole-
cules, to a lesser extent than conventional DCs. In ad-
dition, like their human counterpart, mouse plasma-
cytoid DCs produce a large amount of type I inter-
feron (IFN) following a viral infection and so may
play an important role in antiviral responses rather
than the APC function of T-cell immune response
once activated (Fig. 2).
It has been suggested that mouse plasmacytoid
DCs as well as thymic CD8α+DCs arise as a lymphoid
lineage.36 However, recent studies have proposed
several different hypotheses regarding the complex-
ity of the developmental origin of mouse plasmacy-
toid DCs,36 and the cells may represent a unique he-
matopoietic lineage, whose development may be
much more flexible than that of conventional lym-
phoid (B, T and NK) and myeloid (monocyte and
granulocyte) cells.
The mobilization of mice with FLT3-ligand (Flt3L)
resulted in strikingly increased numbers of plasmacy-
toid DCs in BM and spleen, whereas Flt3L-deficient
mice have fewer plasmacytoid DCs.37-39 Therefore,
Flt3L is the main cytokine for the development of
plasmacytoid DCs from hematopoietic stem cells in
mice. In steady-state conditions, plasmacytoid DCs in
mice have an average turnover of about 2 weeks40
whereas conventional DCs have a rapid turnover,
within 3 to 5 days.41
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Fig. 2 DC subsets and in vivo major function. Immature DC subsets are involved in the induction of peripheral toler-
ance under steady-state conditions possibly mediated through the induction of clonal T-cel deletion as wel as anergic T 
cels and TR cels. Folowing bacterial and viral infections, each immature DC subsets recognizing the pathogens are 
changed into mature DCs, and they elicit various immune responses, depending on their lineage and activation signals.
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HETEROGENEITY OF HUMAN DC SUBSETS
SUBSETS OF CONVENTIONAL HUMAN DCS
In contrast to the extensive research on mouse DCs,
there have been relatively few studies on human DCs
freshly isolated from tissues. Blood samples are the
only readily available source, but human DCs are also
isolated from lymphoid tissues derived from tonsil,
thymus, and spleen in rare cases. Similar to mouse
DCs, human DCs also comprise multiple subsets in
terms of the expression of a range of cell surface
markers, but these might reflect differences in the
maturation status rather than separate sublineages.
Human DCs are also defined by lineage−MHC II+
cells, and all of them express CD4 but lack the ex-
pression of CD8. In addition, human DCs have two
CD11c+ myeloid lineage subsets of conventional DCs
and CD11c− lymphoid lineage subsets of plasmacy-
toid DCs, whereas all subsets of mouse DCs express
CD11c regardless of their developmental lineages.
Human peripheral blood contains two conventional
myeloid DCs. CD4+CD1a+CD11chighBDCA-1CD1c+
subsets (0.6% of PBMCs) and CD4+CD1a−
CD11clowBDCA-3CD141+ subsets (<0.05% of
PBMCs)42-44 (Table 2). CD4+CD1a+CD11chighBDCA-1+
subsets express CD2, CD11b, CD13, CD32, CD33,
CD64, CD45RO and CD116 whereas CD4+CD1a−CD
11clowBDCA-3+ subsets express CD13, CD33, CD45
RO and CD116, but lack the expression of CD2, CD
11b, CD32 and CD64. These conventional myeloid
DC subsets have the capacity to stimulate T cells, and
stimulation with granulocyte-macrophage colony-
stimulating factor (GM-CSF) causes further enhance-
ment.44 CD4+CD1a+CD11chighBDCA-1+ subsets, but
not CD4+CD1a−CD11clowBDCA-3+ subsets, give rise
to cells with characteristics with expression of E-
cadherin, Langerin, Lag Ag, and typical Birbeck gran-
ules under the appropriate culture conditions, and so
CD4+CD1a+CD11chighBDCA-1+ subsets and CD4+
CD1a− CD11clowBDCA-3+ subsets are possibly the di-
rect precursors of LCs and intDCs in peripheral
blood, respectively.42 These conventional DC subsets
can elicit Th1- or Th2-response, depending on the in-
flammatory environments (Fig. 2).45-47
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Table 2 Heterogeneity of human peripheral blood DCs
＊PlasmacytoidConventional
DC Subsets
IPCsCD4＋CD1a－CD11clowCD4＋CD1a＋CD11chigh
LymphoidMyeloidMyeloidLineage
Phenotype
－－＋＋CD1a
－－＋＋CD2
＋＋＋＋＋＋CD4
－－－CD8
－－＋CD11b
－＋＋＋＋＋CD11c
－＋＋＋＋CD13
－－＋＋CD32
－＋＋＋CD33
＋＋－－CD45RA
－＋＋CD45RO
－－＋CD64
－＋＋＋＋CD116
＋＋＋var.＋＋CD123
－－＋＋BDCA-1
＋＋－－BDCA-2
－＋＋－BDCA-3
＋＋－－BDCA-4
－＋＋CD40
＋＋＋CD80
－＋＋CD86
＋＋＋＋＋＋＋＋MHCI
－, negative; ＋, low; ＋＋, intermediate; ＋＋＋, high; var., heterogenous.
HUMAN PLASMACYTOID DCS
Plasmacytoid DCs are recognized as unique DC sub-
sets of lymphoid origin in humans.4 More than 40
years ago, a previously unrecognized rare cell type
was identified in the paracortical areas of reactive
lymph nodes with a morphology similar to that of
plasma cells and with T-cell and monocyte markers,
and therefore designated plasmacytoid T cells or
plasmacytoid monocytes. Although these leukocytes
are poor stimulators of T cells, they developed into
cells with a mature IDC morphology and acquired
the ability to activate naïve T cells when cultured
with IL-3 and CD40L, and were identical to immature
DCs. Moreover, such circulating immature DCs were
found to represent a small leukocyte population that
produced large amounts of type I IFN in response to
certain viruses.3,48,49 Finally, plasmacytoid mono-
cytes, natural IFN-producing cells (IPCs), and imma-
ture DCs in peripheral blood and tonsils were con-
firmed to be the same cell type termed plasmacytoid
DCs (Fig. 2). Human plasmacytoid DCs were origi-
nally identified by lineage−MHC II+CD11c−CD4+
CD45RA+CD123+ILT3+ILT1− subsets (0.4% of
PBMCs) with a lack of other myeloid markers ob-
served in conventional DC subsets, and two addi-
tional markers, BDCA-2CD303 and BDCA-4CD304,
are restricted to human plasmacytoid DCs in periph-
eral blood and BM497 (Table 2). Analysis of the ability
of human plasmacytoid DCs to prime naïve CD4+T
cells suggest that they induce not only Th1- and Th2-
responses but also tolerance in vivo (Fig. 2).46,47
In contrast to the survival effect of GM-CSF on two
(conventional human DC) subsets through the CD
116GM-CSF receptor α-chain (GM-CSFRα), the sur-
vival effect of IL-3 on human plasmacytoid DCs de-
pended on the expression of the CD123IL-3 receptor
α-chain (IL-3Rα).50 The administration of Flt3L to
healthy human volunteers dramatically increases
both myeloid and plasmacytoid DCs, whereas granu-
locyte colony-stimulating factor (G-CSF) only in-
creases plasmacytoid DCs.51
IN VITRO GENERATION OF DCS FROM HU-
MAN AND MOUSE PRECURSOR CELLS
Because DCs are rare in the body and therefore the
isolation procedures are time consuming and cell
yields are low. The methodology for generating a
large numbers of DCs from precursor cells and their
analysis has proven crucial for a better understanding
of the biology of natural occurring DCs.
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IN VITRO GENERATION OF MURINE CONVEN-
TIONAL AND PLASMACYTOID DCS
Mouse conventional myeloid DCs are generated from
mouse BM or from peripheral blood monocytes with
GM-CSF, or GM-CSF plus IL-4.38,52 On the other
hand, the development of murine plasmacytoid DCs
as well as myeloid DCs is promoted by Flt3L in total
BM cultures, while GM-CSF or tumor necrosis factor
(TNF)-α inhibits the development of murine plasma-
cytoid DCs, but promots the development of myeloid
DCs in vitro.37 Although naturally occurring mouse
DCs consist of CD4+subsets, CD8αhighsubsets and
CD4−CD8α− subsets, cultures only generate CD4−CD
8α− subsets regardless of lineage and the develop-
mental pathway.
IN VITRO GENERATION OF HUMAN CONVEN-
TIONAL AND PLASMACYTOID DCS
Two different precursors have been used to generate
human DCs in culture. The earliest precursors used
are the CD34+ fraction isolated from BM or umbilical-
cord blood. Liquid culture with GM-CSF and TNF-α
leads to intDC-like subsets and LC-like subsets.4,53 In
addition, c-kit ligand increases the total number of
cultured myeloid DCs in synergistic combination
with GM-CSF and TNF-α,54 and transforming growth
factor (TGF)-β1 promotes in vitro development of LC-
like subsets from CD34+ hemopoietic progenitors.55
On the other hand, Flt3L, but not G-CSF, has been
shown to induce a proportion of human CD34+CD45
RA− early hematopoietic stem cells to differentiate
into human plasmacytoid DCs in culture.56
Blood monocytes are the most commonly used
precursor cells for generating human DCs in culture.
Blood monocytes cultured with GM-CSF and IL-4 dif-
ferentiate into immature myeloid DCs57 whereas they
develop into LC-like subsets in the presence of GM-
CSF, IL-4 and TGF-β1,58 and little or no proliferative
expansion is involved. The final maturation of these
DC subsets, which is associated with the expression
of CD83 as well as upregulation of costimulatory
molecules and MHC II, is achieved by stimulating the
cells with bacterial products such as lipopolysacccha-
ride (LPS) and proinflammatory cytokines such as
TNF-α for experimental procedures and cytokine
cocktails containing TNF-α, IL-1β, IL-6 and
prostaglandin E2 (PGE2) for clinical use.59
CONCLUDING REMARKS
Many important aspects of the biology of DCs have
been revealed through the extensive recent study of
the characteristics and role of these cells in acquired
and innate immune responses. The remarkable func-
tional diversity of DC subsets endows the immune
system with the flexibility to mount appropriate im-
mune responses, and the dynamics of such a flexible
and responsive DC system might be dictated by sub-
set heterogeneity dependent on maturity and lineage
origin, and functional plasticity. However, there are
still unsolved mysteries regarding origin, function,
and the molecular events governing their characteris-
tic features. Answering these questions will provide
us with a better understanding of not only the rela-
tionship between subset heterogeneity and functional
plasticity but also the precise role of DCs in immunity
and tolerance. In addition, they may also point to
novel targets for the improvement of DC-based vac-
cines in order to enhance insufficient immune re-
sponses in patients with infectious diseases and can-
cer, and to attenuate excessive undesired immune re-
sponses in graft-versus-host diseases (GVHD), graft
rejection, allergy and autoimmunity.
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